Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 5 minute read Pharma Industry News CSL wins FDA approval for ANDEMBRY, the first monthly anti-factor XIIa therapy for hereditary angioedema CSL’s ANDEMBRY gains U.S. FDA approval as the first monthly HAE treatment targeting factor XIIa. Learn how it redefines disease control for patients. byPallavi MadhirajuJune 17, 2025